Checkpoint inhibitors in breast cancer - Current status

Keyphrases

• Breast Cancer 100%
• Triple-negative Breast Cancer 100%
• Checkpoint Inhibitors 100%
• Breast Cancer Patients 50%
• Embase 50%
• Number of Patients 50%
• Clinical Development 50%
• PubMed 50%
• Monotherapy 50%
• Patient Selection 50%
• Literature Search 50%
• Treatment Modalities 50%
• Computer-based 50%
• Overall Survival 50%
• Chemotherapy 50%
• Predictive Biomarker 50%
• Progression-free Survival 50%
• Further Development 50%
• Pathological Response 50%
• Overall Response Rate 50%
• Multiple Trials 50%
• Tumor Immunity 50%
• Neoadjuvant Setting 50%
• Anticancer Agents 50%
• Programmed Death-ligand 1 (PD-L1) 50%
• Immune Checkpoint 50%
• PD-1 Pathway 50%
• International Meeting 50%
• Heavily Pretreated 50%
• Immune Checkpoint Inhibitors 50%
• Tumor Remission 50%

Medicine and Dentistry

• Breast Cancer 100%
• Biological Marker 66%
• Triple Negative Breast Cancer 66%
• Patient Selection 33%
• Overall Survival 33%
• Monotherapy 33%
• Progression Free Survival 33%
• Anticarcinogen 33%
• Standing 33%
• Tumor Regression 33%
• Tumor Immunity 33%
• Programmed Death-Ligand 1 33%
• Immune Checkpoint Inhibitor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Biological Marker 66%
• Triple Negative Breast Cancer 66%
• Neoplasm 33%
• Monotherapy 33%
• Overall Survival 33%
• Chemotherapy 33%
• Progression Free Survival 33%
• Tumor Regression 33%
• Anticarcinogen 33%
• Immune Checkpoint Inhibitor 33%